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Abstract			
Introduction:		The	high	risk	of	cardiovascular	events	in	smokers	requires	adequate	control	of	other	cardiovascular	risk	factors	(CVRFs)	to	curtail	atherosclerosis	progression.	However,	it	is	unclear	which	CVRFs	have	the	most	influence	on	atherosclerosis	progression	in	smokers.		
Methods:		In	260	smokers	aged	40-70	included	in	a	smoking	cessation	trial,	we	analyzed	the	association	between	traditional	CVRFs,	high-sensitivity	C	reactive	protein	(hs-CRP),	smoking	cessation	and	3-year	progression	of	carotid	intima-media	thickness	(CIMT,	assessed	by	repeated	ultrasound	measurements)	in	a	longitudinal	multivariate	model.		
Results:		Participants	(mean	age	52	years,	47%	women)	had	a	mean	smoking	duration	of	32	years	with	a	median	daily	consumption	of	20	cigarettes.	Baseline	CIMT	was	1185μm	(95%CI:1082-1287)	and	increased	by	93μm	(95%CI:25-161)	and	108μm	(95%CI:33-183)	after	one	and	three	years,	respectively.	Age,	male	sex,	daily	cigarette	consumption,	systolic	blood	pressure	(SBP),	but	neither	LDL-cholesterol	nor	hs-CRP,	were	independently	associated	with	baseline	CIMT	(all	p≤0.05).	Baseline	SBP,	but	neither	LDL-cholesterol	nor	hs-CRP,	was	associated	with	3-year	atherosclerosis	progression	(p=0.01	at	3	years).	The	higher	the	SBP	at	baseline,	the	steeper	was	the	CIMT	increase	over	3-year	follow-up.	We	found	an	increase	of	26μm	per	each	10mmHg	raise	in	SBP	at	one	year	and	an	increase	of	39μm	per	each	10mmHg	raise	in	SBP	at	three	years.	Due	to	insufficient	statistical	power, we	could	not	exclude	an	effect	of	smoking	abstinence	on	CIMT	progression.	
Conclusion:		
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Control	of	blood	pressure	may	be	an	important	factor	to	limit	atherosclerosis	progression	in	smokers,	besides	support	for	smoking	cessation.			
Implications	Among	260	smokers	aged	40-70	years	with	a	mean	smoking	duration	of	32	years,	baseline	systolic	blood	pressure	was	associated	with	atherosclerosis	progression	over	3	years,	as	measured	by	carotid	intima-media	thickness	(CIMT,	p=0.01	at	3	years),	independently	of	smoking	variables	and	other	cardiovascular	risk	factors.	The	higher	the	SBP	at	baseline,	the	steeper	was	the	CIMT	increase	over	3-year	follow-up.	Our	findings	emphasize	the	importance	of	focusing	not	only	on	smoking	cessation	among	smokers,	but	to	simultaneously	control	other	cardiovascular	risk	factors,	particularly	blood	pressure,	in	order	to	prevent	future	cardiovascular	disease.		
Key	Words:	smoking;	carotid	artery	disease;	risk	factors;	ultrasonography;	intima-media	thickness;	C-reactive	protein.	
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Introduction	Smoking	increases	the	risk	of	cardiovascular	diseases	(CVD)	by	enhancing	atherosclerosis	process1–4	and	shifting	the	balance	of	homeostasis	towards	thrombus	formation4,5.	Several	studies	have	shown	an	association	between	smoking	and	carotid	intima-media	thickness	(CIMT)2,6–8,	atherosclerotic	disease9	and	CIMT	progression10.	Besides	smoking,	traditional	cardiovascular	risk	factors	(CVRFs),	such	as	age,	male	sex,	hypertension,	hypercholesterolemia,	diabetes	and	obesity,	have	also	been	associated	with	the	atherosclerosis	progression7,8,11–14.	Most	previous	studies	examining	the	role	of	CVRFs	with	atherosclerosis	development	were	conducted	in	mixed	populations	consisting	of	smokers,	former	smokers	and	non-smokers15,16,	or	often	focused	on	young	populations10.	However,	there	are	few	available	data	regarding	smokers	only,	and	not	all	smokers	are	at	similar	risk	for	CVD,	because	intensity	of	exposure	influences	atherosclerosis	development17.		Thus,	it	remains	unclear	which	CVRFs	have	the	most	influence	on	atherosclerosis	progression	in	smokers.	Therefore,	we	examined	whether	traditional	CVRFs,	subclinical	inflammation	and	smoking	cessation	were	associated	with	atherosclerosis	progression	over	a	3-year	follow-up	in	smokers	included	in	a	smoking	cessation	trial18.			
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Methods	We	prospectively	studied	smokers	aged	40-70	years	without	preexisting	CVD	from	the	CAROtid	plaque	Screening	trial	on	Smoking	cessation	(CAROSS),	a	randomized	controlled	trial18,19	designed	to	assess	the	benefit	of	carotid	atherosclerotic	disease	screening	along	with	advice	to	quit	smoking.	Details	of	the	methods	have	been	previously	reported19.		Current	smokers	of	≥10	cigarettes/day	motivated	to	quit	were	recruited	through	newspaper	advertisements.	536	participants	aged	40-70,	without	preexisting	CVD,	were	included	and	randomized	into	carotid	atherosclerotic	disease	screening	by	ultrasound	(intervention	group)	vs.	no	ultrasound	(control	group)	in	addition	to	smoking	cessation	counseling	for	both	groups.	We	examined	266	smokers	of	the	intervention	group	screened	by	ultrasound	for	atherosclerosis	at	baseline	and	with	ultrasound	data	at	1	and	3-year	follow-up.	Six	participants	were	excluded	due	to	missing	laboratory	data	or	non-measurable	carotid	plaques.	Thus	data	on	260	participants	were	available	for	the	current	analysis.	
	
Cardiovascular	risk	factors	As	previously	described19,	we	collected	demographics,	physical	activity,	medical	and	smoking	history,	and	medication	use	at	baseline.	We	measured	weight,	height,	blood	pressure	(BP),	and	fasting	plasma	levels	of	lipids	and	glucose	using	standardized	techniques.	BP	was	measured	using	a	standard	sphygmomanometer	after	a	10-minute	rest	in	seated	position20.	The	right-arm	BP	was	assessed	at	three	1-minute-intervals,	the	two	final	BP	averaged	to	reduce	variability.	Hypertension	was	defined	as	systolic	blood	pressure	(SBP)	≥140mmHg	and/or	diastolic	blood	pressure	(DBP)	≥90mmHg;	or	SBP	≥130mmHg	and/or	DBP	≥80mmHg	for	participants	with	diabetes,	and/or	on	anti-hypertensive	treatment20.	Hypercholesterolemia	was	defined	as	LDL-cholesterol	over	
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target	value	recommended	by	ATP-III	guidelines21	or	on	lipid-lowering	medication.	Diabetes	was	defined	as	fasting	plasma	glucose	≥7.0mmol/l	or	on	anti-diabetic	treatment22.	High-sensitivity	C-reactive	protein	(hs-CRP)	was	measured	by	immunonephelemetric	assay	(Siemens	Healthcare	Diagnostics,	Marburg,	Germany).	Duration	of	smoking	before	inclusion	in	the	study	was	calculated	by	deducting	self-reported	periods	of	abstinence.	We	defined	continuous	abstinence	during	follow-up	as	complete	smoking	cessation	between	baseline	and	follow-up	visits,	with	repeated	biochemical	validation	of	smoking	status	by	exhaled	carbon	monoxide	and	plasma	cotinine	measurements18.		Participants	who	were	smoking	at	the	time	of	1-year	or	3-year	follow-up	visits	were	defined	as	1-year	or	3-year	relapse.	The	local	Ethical	Committee	approved	the	study	and	all	participants	gave	written	informed	consent.		
B-mode	ultrasound	examination	Participants	had	B-mode	carotid	ultrasound	screening	for	atherosclerotic	lesions	(System	5;	Vingmed,	General	Electric),	performed	by	a	trained	observer	blinded	to	clinical	information	at	baseline,	1	year,	and	3	years.	The	intraobserver	variability	showed	95%	agreement	between	the	first	and	second	reading	among	20	randomly	selected	subjects18.	We	measured	maximal	CIMT	of	the	right	and	left	carotid	artery	bifurcation	and	averaged	both	to	obtain	mean	maximal	CIMT23. The	current	resolution	of	1	pixel	corresponds	to	a	surface	of	54x54μm.	Measurements	were	conducted	according	to	the	recommendations	of	the	US	Task	Force	on	noninvasive	atherosclerosis	measurement24	and	similar	to	the	Rotterdam	Study18,25.		
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Statistical	analysis	A	multivariate	longitudinal	model	was	used	to	assess	the	association	between	baseline	CVRFs	and	CIMT	and	its	progression	over	3-year	follow-up.	Longitudinal	models	are	methods	of	choice	for	analyzing	data	with	repeated	measures	for	each	participant26,27	and	allow	to	estimate	an	adjusted	mean	outcome	trajectory,	taking	into	account	the	inter-individual	variability28,29.	In	addition,	they	can	deal	with	unbalanced	data	due	to	drop-out	and	missing	values.	To	account	for	their	additive	effect,	all	baseline	CVRFs	were	entered	in	the	model,	smoking	abstinence	as	a	time-varying	covariable.	CVRFs	with	skewed	distributions	(number	of	cigarettes	per	day;	hs-CRP)	were	log-transformed.	Three	smoking	abstinence	trajectories	were	considered,	corresponding	to	different	levels	of	smoking	exposure,	depending	on	abstinence	status	at	each	follow-up	visit:	“one-year	relapse”,	“one-year	continuous	abstinence	and	three-year	relapse”,	and	“three-year	continuous	abstinence”.		We	also	tested	for	possible	interactions	between	smoking	abstinence	and	SBP	and	LDL-cholesterol	respectively.	For	this	analysis,	smoking	abstinence	was	dichotomized	in	‘at	least	one	year	continuous	abstinence’	and	‘relapse’	for	better	legibility	of	the	results.	Statistical	analyses	were	performed	using	R	software	package	(version	2.15.1,	GNU	Project,	University	of	Auckland,	New	Zealand).	
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Results	
Baseline	characteristics	of	the	260	participants	are	described	in	Table	1.	Participants	had	a	mean	duration	of	32	years	of	smoking	and	a	large	prevalence	of	CVRFs.	Forty-one	participants	could	not	be	assessed	for	CIMT	at	1-year	and	83	participants	at	3-year	follow-up.	There	was	no	significant	difference	between	baseline	characteristics	of	participants	without	CIMT	measurements	at	3-year	follow-up	(n=83)	compared	to	those	with	follow-up	(n=177),	except	for	a	borderline	statistically	significant	lower	SBP	(p=0.05).		Estimated	CIMT	progression	was	93μm	after	1-year	and	108µm	after	3-year	follow-up,	respectively	(Table	2,	Appendix	Figure).	A	dose-response	relationship	was	found	between	number	of	cigarettes	per	day	at	baseline	and	baseline	CIMT	(p=0.03).	Male	sex,	age	and	SBP	were	also	significantly	associated	with	baseline	CIMT	(all	p£0.05)	(Table	2).	For	instance,	baseline	CIMT	is	estimated	to	be	50.8μm	larger	per	each	10mmHg	increase	in	baseline	SBP.	In	both	sexes,	1-year	and	3-year	CIMT	progression	was	similar	(p	for	interaction=	0.96	and	p=0.97,	respectively),	but	baseline	CIMT	differed	(p=	0.04)	(Table	2,	Appendix	Figure).		Baseline	SBP	was	also	associated	with	CIMT	progression	over	3-year	follow-up,	showing	borderline	significance	at	1-year	(p=0.06)	and	significance	at	3-year	follow-up	(p=0.01).	CIMT	increase	at	one	year	was	estimated	to	be	26μm	larger	per	each	10mmHg	increase	in	SBP	(Table	2)	and	39μm	larger	per	each	10mmHg	increase	in	SBP	at	three	years	compared	to	baseline	(Table	2).	Thus,	the	higher	the	SBP	at	baseline,	the	steeper	was	the	CIMT	increase	over	3-year	follow-up	for	both	female	and	male	participants	(Appendix	Figure).	We	found	no	significant	associations	of	gender	with	the	progression	of	CIMT	
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(p=0.96	at	1-year,	p=0.97	at	3-year	follow-up).	In	a	sensitivity	analysis,	we	added	the	covariables	of	medication	for	hypertension,	hypercholesterolemia	and	hyperglycemia	at	baseline	in	our	longitudinal	model;	none	of	the	three	covariables	showed	a	significant	association	with	CIMT,	but	SBP	remained	significantly	associated	with	baseline	CIMT	(p=0.05)	and	after	3	years	(p=0.02),	comparable	to	results	in	Table	2.	An	attenuation	in	CIMT	progression	was	observed	after	one	and	three	years	of	continuous	abstinence	with	respect	to	the	reference	group	(1-year	relapse),	although	not	reaching	statistical	significance	(Table	2).		We	did	not	find	statistically	significant	interactions	between	continuous	smoking	abstinence	and	SBP	or	LDL-cholesterol	after	3-year	follow-up	(p=0.23	and	p=0.15	respectively).	
 
Discussion	Among	smokers,	we	found	that	BP	was	associated	with	atherosclerosis	progression	over	3-year	follow-up	beyond	smoking	variables	and	other	CVRFs.	By	contrast,	we	did	not	find	an	association	between	subclinical	inflammation	measured	by	hs-CRP,	or	other	CVRFs	and	atherosclerosis	progression.		Few	data	exist	about	the	association	of	CVRFs	and	carotid	atherosclerosis	progression	in	smokers.	Our	results	are	consistent	with	the	San	Daniele	Project	that	found	that	age,	SBP	and	smoking	were	associated	with	carotid	plaques	in	participants	>39	years	both	at	baseline7	and	at	12-year	follow-up8.	However,	smoking	duration	was	not	reported	in	this	study	and	definitive	or	transient	smoking	cessation	was	likely	not	taken	into	account	in	these	analyses.	Johnson	et	al.10	found	an	association	between	SBP	and	CIMT	progression	as	well	as	the	number	of	cigarettes	smoked	per	day.	However,	this	study	focused	on	young	adults	(n=336,	mean	age	32	years)	and	neither	the	association	
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between	LDL-cholesterol	and	CIMT	progression,	nor	the	prevalence	of	hypertension	was	reported.	Similar	to	our	study,	a	randomized	controlled	trial	of	smoking	cessation	among	795	smokers	with	a	3-year	follow-up11	found	that	antihypertensive	medication	use	was	associated	with	increase	of	CIMT	(i.e.	an	indirect	indication	that	BP	was	associated	with	CIMT).	However,	participants	with	uncontrolled	hypertension	(BP>160/100mmHg)	were	excluded	and	the	proportion	of	patients	with	hypertension	was	not	mentioned.	Similar	to	our	study,	smoking	status	(cessation	or	continuation)	during	3-year	follow-up	did	not	predict	CIMT	progression	beyond	CVRFs.			Hs-CRP	was	not	associated	with	CIMT	in	our	multivariate	analysis,	neither	at	baseline,	nor	after	1	or	3-year	follow-up.	This	finding	is	consistent	with	the	results	by	Lorenz	et	al.16,	which	demonstrated	that	the	association	between	hs-CRP	and	baseline	CIMT	disappeared	after	controlling	for	conventional	CVRFs.		The	absence	of	an	association	between	hs-CRP	and	carotid	plaques	in	multivariate	analysis	was	also	shown	by	Molino-Lova	et	al.15.	However,	this	study	showed	a	significant	association	between	higher	hs-CRP	levels	and	the	3-year	incidence	of	carotid	plaques,	hypothesizing	that	hs-CRP	represents	the	overall	inflammatory	burden	or	the	early	stage	of	vessel	inflammation.	Both	of	the	above	mentioned	studies	included	smokers	and	non-smokers	without	specifying	their	respective	repartition	and	hs-CRP	levels	in	smokers	were	not	compared	to	those	in	non-smokers.	Our	study	is	the	first	to	focus	on	smokers	only	and	the	absence	of	an	association	between	hs-CRP	and	CIMT	is	generally	consistent	with	increasing	evidence	that	CRP	is	a	marker	but	not	an	independent	risk	factor	of	CVD,	as	shown	for	example	in	Mendelian	randomization	studies30.			
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In	our	results,	LDL-cholesterol	had	a	pattern	of	association	(albeit	not	statistically	significant)	with	baseline	CIMT,	but	not	with	CIMT	progression.	A	similar	finding	by	Molino-Lova	et	al.15	showed	no	significant	association	between	baseline	LDL-cholesterol	and	the	appearance	of	new	carotid	plaques	over	3	years.	Johnson	et	al.11	described	an	association	between	3-year	changes	in	LDL-cholesterol	and	CIMT	progression,	but	did	not	examine	the	association	of	baseline	LDL-cholesterol	and	CIMT	progression.	A	longer	follow-up	period	might	be	needed	to	detect	a	possible	association	between	LDL-cholesterol	and	CIMT	progression,	although	a	3-year	follow-up	revealed	an	association	with	BP.		Our	study	had	several	limitations.	By	design,	we	included	only	smokers	motivated	to	quit	and	these	persons	might	have	healthier	behaviors	than	average	smokers.	However,	the	prevalence	of	CVRFs	was	high	at	baseline.	Calculation	of	smoking	abstinence	relied	on	self-reported	abstinence,	confirmed	by	measurement	of	exhaled	carbon	monoxide	and	serum	cotinine	at	follow-	up	visits18.	However,	we	could	not	exclude	smoking	exposure	between	visits.	Although	CIMT	progression	was	slower	in	participants	continuously	abstinent	compared	to	those	relapsing	after	1	year,	these	results	did	not	reach	statistical	significance,	likely	because	our	sample	size	was	relatively	small.	Our	study	may	have	been	underpowered	to	demonstrate	weak	associations	of	other	risk	factors	or	continued	smoking	cessation	on	CIMT	progression.	As	we	did	not	measure	genetic	factors,	we	could	not	assess	their	effect	on	CIMT.		Among	strengths,	we	were	able	to	analyze	data	of	a	3-year	follow-up,	as	well	as	characterize	participants	accurately	according	to	smoking	exposure,	expressed	as	number	of	cigarettes	per	day,	years	of	smoking	and	pack-years,	as	well	as	smoking	status	during	the	study	follow-up,	compared	to	previous	studies3,8,9.	Although	the	
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sample	was	not	large	enough	to	assess	small	effects	of	exposures,	particularly	that	of	smoking	discontinuation,	our	study	is	one	of	the	largest	to	assess	the	impact	of	CVRFs	among	well-characterized	smokers.		In	conclusion,	several	CVRFs	in	smokers	are	associated	with	carotid	atherosclerosis	in	cross-sectional	analyses,	but	BP	was	the	strongest	predictor	of	atherosclerosis	progression	among	smokers.	Hs-CRP	is	not	associated	with	baseline	or		carotid	atherosclerosis	progression.	Our	findings	emphasize	the	importance	of	focusing	not	only	on	smoking	cessation	among	smokers,	but	to	simultaneously	control	other	CVRFs,	particularly	BP,	in	order	to	prevent	future	CVD.	
 
Acknowledgements	This	study	was	supported	by	research	grants	from	the	Swiss	National	Science	Foundation	(SNSF	3200B0-116097	to	Prof	Rodondi),	the	Swiss	Heart	Foundation,	the	University	Hospital	Strategic	Plan	and	the	Swiss	Tobacco	Prevention	Funds,	Federal	Office	of	Public	Health	(FPT	08.002282).	Prof	Rodondi’s	research	is	also	supported	by	grants	of	the	Swiss	National	Science	Foundation	(SNSF	320030-150025)	and	from	the	Swiss	Heart	Foundation.	Dr	T-H	Collet’s	research	is	supported	by	grants	from	the	Swiss	National	Science	Foundation	and	the	Swiss	Foundation	for	Grants	in	Biology	and	Medicine	(PBLAP3-145870,	P3SMP3-155318).		
Declaration	of	Conflicting	Interests	None	declared.	
  
13	
References	1.		 Erhardt	L.	Cigarette	smoking:	an	undertreated	risk	factor	for	cardiovascular	disease.	Atherosclerosis.	2009;205(1):23–32.	doi:10.1016/j.atherosclerosis.2009.01.007.	2.		 Johnson	HM,	Piper	ME,	Jorenby	DE,	Fiore	MC,	Baker	TB,	Stein	JH.	Risk	factors	for	subclinical	carotid	atherosclerosis	among	current	smokers.	Prev	Cardiol.	2010;13(4):166–71.	doi:10.1111/j.1751-7141.2010.00068.x.	3.		 Mähönen	MS,	McElduff	P,	Dobson	a	J,	Kuulasmaa	K	a,	Evans	a	E.	Current	smoking	and	the	risk	of	non-fatal	myocardial	infarction	in	the	WHO	MONICA	Project	populations.	Tob	Control.	2004;13(3):244–50.	doi:10.1136/tc.2003.003269.	4.		 Csordas	A,	Bernhard	D.	The	biology	behind	the	atherothrombotic	effects	of	cigarette	smoke.	Nat	Rev	Cardiol.	2013;10(4):219–30.	doi:10.1038/nrcardio.2013.8.	5.		 Matetzky	S,	Tani	S,	Kangavari	S,	et	al.	Smoking	Increases	Tissue	Factor	Expression	in	Atherosclerotic	Plaques :	Implications	for	Plaque	Thrombogenicity.	Circulation.	2000;102(6):602–604.	doi:10.1161/01.CIR.102.6.602.	6.		 Baldassarre	D,	Castelnuovo	S,	Frigerio	B,	et	al.	Effects	of	timing	and	extent	of	smoking,	type	of	cigarettes,	and	concomitant	risk	factors	on	the	association	between	smoking	and	subclinical	atherosclerosis.	Stroke.	2009;40(6):1991–1998.	doi:STROKEAHA.108.543413	[pii]	10.1161/STROKEAHA.108.543413.	7.		 Prati	P,	Vanuzzo	D,	Casaroli	M,	et	al.	Prevalence	and	determinants	of	carotid	atherosclerosis	in	a	general	population.	Stroke.	1992;23(12):1705–1711.	doi:10.1161/01.STR.23.12.1705.	8.		 Prati	P,	Vanuzzo	D,	Casaroli	M,	et	al.	Determinants	of	carotid	plaque	occurrence.	A	long-term	prospective	population	study:	the	San	Daniele	Project.	Cerebrovasc	Dis.	2006;22(5-6):416–422.	doi:CED20060225_6416	[pii]	10.1159/000094993.	9.		 Tell	GS,	Polak	JF,	Ward	BJ,	Kittner	SJ,	Savage	PJ,	Robbins	J.	Relation	of	smoking	with	carotid	artery	wall	thickness	and	stenosis	in	older	adults.	The	Cardiovascular	Health	Study.	The	Cardiovascular	Health	Study	(CHS)	Collaborative	Research	Group.	Circulation.	1994;90(6):2905–2908.	doi:10.1161/01.CIR.90.6.2905.	10.		 Johnson	HM,	Douglas	PS,	Srinivasan	SR,	et	al.	Predictors	of	carotid	intima-media	thickness	progression	in	young	adults:	the	Bogalusa	Heart	Study.	Stroke.	2007;38(3):900–5.	doi:10.1161/01.STR.0000258003.31194.0a.	11.		 Johnson	HM,	Piper	ME,	Baker	TB,	Fiore	MC,	Stein	JH.	Effects	of	smoking	and	cessation	on	subclinical	arterial	disease:	a	substudy	of	a	randomized	controlled	trial.	PLoS	One.	2012;7(4):e35332.	doi:10.1371/journal.pone.0035332.	12.		 Dalmas	E,	Kahn	J-F,	Giral	P,	et	al.	Intima-media	thickness	in	severe	obesity:	links	with	BMI	and	metabolic	status	but	not	with	systemic	or	adipose	tissue	inflammation.	Diabetes	Care.	2013;36(11):3793–802.	doi:10.2337/dc13-0256.	13.		 Urbina	EM,	Srinivasan	SR,	Tang	R,	Bond	MG,	Kieltyka	L,	Berenson	GS.	Impact	of	multiple	coronary	risk	factors	on	the	intima-media	thickness	of	different	segments	of	carotid	artery	in	healthy	young	adults	(The	Bogalusa	Heart	Study).	
Am	J	Cardiol.	2002;90(9):953–958.	doi:10.1016/S0002-9149(02)02660-7.	14.		 Vergeer	M,	Zhou	R,	Bots	ML,	et	al.	Carotid	atherosclerosis	progression	in	familial	hypercholesterolemia	patients:	A	pooled	analysis	of	the	ASAP,	ENHANCE,	RADIANCE	1,	and	CAPTIVATE	studies.	Circ	Cardiovasc	Imaging.	2010;3(4):398–404.	doi:10.1161/CIRCIMAGING.109.909655.	
  
14	
15.		 Molino-Lova	R,	Macchi	C,	Gori	a	M,	et	al.	High	sensitivity	C-reactive	protein	predicts	the	development	of	new	carotid	artery	plaques	in	older	persons.	Nutr	
Metab	Cardiovasc	Dis.	2011;21(10):776–82.	doi:10.1016/j.numecd.2010.02.003.	16.		 Lorenz	MW,	Karbstein	P,	Markus	HS,	Sitzer	M.	High-sensitivity	C-reactive	protein	is	not	associated	with	carotid	intima-media	progression:	the	carotid	atherosclerosis	progression	study.	Stroke.	2007;38(6):1774–9.	doi:10.1161/STROKEAHA.106.476135.	17.		 Streppel	MT,	Boshuizen	HC,	Ocké	MC,	Kok	FJ,	Kromhout	D.	Mortality	and	life	expectancy	in	relation	to	long-term	cigarette,	cigar	and	pipe	smoking:	the	Zutphen	Study.	Tob	Control.	2007;16(2):107–13.	doi:10.1136/tc.2006.017715.	18.		 Rodondi	N,	Collet	T-H,	Nanchen	D,	et	al.	Impact	of	carotid	plaque	screening	on	smoking	cessation	and	other	cardiovascular	risk	factors:	a	randomized	controlled	trial.	Arch	Intern	Med.	2012;172(4):344–52.	doi:10.1001/archinternmed.2011.1326.	19.		 Rodondi	N,	Bovet	P,	Hayoz	D,	Cornuz	J.	The	Impact	of	CAROtid	plaque	Screening	on	Smoking	(CAROSS)	cessation	and	control	of	other	cardiovascular	risk	factors:	Rationale	and	design	of	a	randomized	controlled	trial.	Contemp	Clin	Trials.	2008;29(5):767–73.	doi:10.1016/j.cct.2008.03.001.	20.		 Chobanian	A	V,	Bakris	GL,	Black	HR,	et	al.	The	Seventh	Report	of	the	Joint	National	Committee	on	Prevention,	Detection,	Evaluation,	and	Treatment	of	High	Blood	Pressure:	the	JNC	7	report.	JAMA.	2003;289(19):2560–72.	doi:10.1001/jama.289.19.2560.	21.		 NCEP	Expert	Panel.	Executive	Summary	of	the	Third	Report	of	the	National	
Cholesterol	Education	Program	(NCEP)	Expert	Panel	on	Detection,	Evaluation,	and	
Treatment	of	High	Blood	Cholesterol	in	Adults	(Adult	Treatment	Panel	III)	Expert	
Panel	On	Detection,	Evaluation	And	Treat.;	2001.	doi:10.1001/jama.285.19.2486.	22.		 ADA.	Standards	of	medical	care	in	diabetes--2010.	Diabetes	Care.	2010;33	Suppl	1:S11–61.	doi:10.2337/dc10-S011.	23.		 Touboul	P-J,	Hennerici	MG,	Meairs	S,	et	al.	Mannheim	carotid	intima-media	thickness	and	plaque	consensus	(2004-2006-2011).	An	update	on	behalf	of	the	advisory	board	of	the	3rd,	4th	and	5th	watching	the	risk	symposia,	at	the	13th,	15th	and	20th	European	Stroke	Conferences,	Mannheim,	Germany,	2004,	B.	
Cerebrovasc	Dis.	2012;34(4):290–6.	doi:10.1159/000343145.	24.		 Redberg	RF,	Vogel	RA,	Criqui	MH,	Herrington	DM,	Lima	JA,	Roman	MJ.	34th	Bethesda	Conference:	Task	force	#3--What	is	the	spectrum	of	current	and	emerging	techniques	for	the	noninvasive	measurement	of	atherosclerosis?	J	Am	
Coll	Cardiol.	2003;41(11):1886–1898.	doi:S0735109703003607	[pii].	25.		 Van	der	Meer	IM,	Bots	ML,	Hofman	A,	del	Sol	AI,	van	der	Kuip	D	a	M,	Witteman	JCM.	Predictive	value	of	noninvasive	measures	of	atherosclerosis	for	incident	myocardial	infarction:	the	Rotterdam	Study.	Circulation.	2004;109(9):1089–94.	doi:10.1161/01.CIR.0000120708.59903.1B.	26.		 Cnaan	A,	Laird	NM,	Slasor	P.	Using	the	general	linear	mixed	model	to	analyse	unbalanced	repeated	measures	and	longitudinal	data.	Stat	Med.	1997;16(20):2349–80.	doi:10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E.	27.		 Gibbons	RD,	Hedeker	D,	DuToit	S.	Advances	in	analysis	of	longitudinal	data.	Annu	
Rev	Clin	Psychol.	2010;6:79–107.	doi:10.1146/annurev.clinpsy.032408.153550.	28.		 Pinheiro	JC,	Bates	DM.	Mixed-Effects	Models	in	Sand	S-PLUS.	New	York,	NY:	Springer	New	York;	2000.	doi:10.1007/978-1-4419-0318-1.	
  
15	
29.		 Bryk	AS,	Raudenbush	SW.	Hierarchical	linear	models:	Applications	and	data	
analysis	methods.	SAGE;	1992.	30.		 Kivimäki	M,	Lawlor	D	a,	Smith	GD,	et	al.	Does	high	C-reactive	protein	concentration	increase	atherosclerosis?	The	Whitehall	II	Study.	PLoS	One.	2008;3(8):e3013.	doi:10.1371/journal.pone.0003013.	31.		 Friedewald	WT,	Levy	RI,	Fredrickson	DS.	Estimation	of	the	concentration	of	low-density	lipoprotein	cholesterol	in	plasma,	without	use	of	the	preparative	ultracentrifuge.	Clin	Chem.	1972;18(6):499–502.	doi:10.1177/107424840501000106.	32.		 Swiss	Atherosclerosis	Association.	www.agla.ch.	2010.	Available	at:	www.agla.ch.						
  
16	
Table	1.	Characteristics	of	study	participants	(n=260)	
		
Demographics	 	Age,	years,	mean	(SD)	 51.6	(7.6)	Women,	%	(nb)	 46.5	(121)	
Smoking	history		 	Number	of	cigarettes	per	day,	median	[IQR]	 20	[20,	30]	Duration	of	tobacco	smokinga,	years,	mean	(SD)	 32.1	(8.5)	Number	of	pack-years,	mean	(SD)	 39.1	(19.7)	
Cardiovascular	risk	factors	 	Systolic	blood	pressure,	mmHg,	mean	(SD)	 123.7	(15.8)	Hypertensionb,	%	(nb)	 32.7	(85)	HDL	cholesterol,	mmol/l,	mean	(SD)	Calculated	LDL	cholesterolc,	mmol/l,	mean	(SD)	 1.4	(0.41)	3.7	(0.97)	Hypercholesterolemiad,	%	(nb)	 47.3	(123)	Fasting	plasma	glucose,	mmol/l,	mean	(SD)	 4.9	(0.87)	Diabetese,	%	(nb)	 3.8	(10)	hs-CRP,	mg/dl,	median	[IQR]	 1.35	[0.69,	3.01]	
Lifestyle	 	Alcohol,	standard	units	per	weekf,	median	[IQR]	 6	[3,	15]			Abbreviations:	hs-CRP,	high-sensitivity	C-reactive	protein;	IQR,	interquartile	range;	LDL,	low-density	lipoprotein.	a	Periods	of	self-reported	interruption	deducted	b	Hypertension	was	defined	as	systolic	blood	pressure	≥140	mmHg	and/or	diastolic	blood	pressure	≥	90	mmHg;	or	systolic	blood	pressure	≥130	mmHg	and/or	diastolic	blood	pressure	≥80	mmHg	for	participants	with	diabetes;	or	on	anti-hypertensive	treatment	20	c	LDL	cholesterol	was	calculated	according	to	the	Friedewald	equation,	with	the	exclusion	of	1participant	with	fasting	triglycerides	above	4.5	mmol/l	(400	mg/dl)	31	d	Hypercholesterolemia	was	defined	as	LDL	cholesterol	over	target	value	recommended	by	NCEP	ATP-III	guidelines		or	on	lipid-lowering	medication	32	e	Diabetes	was	defined	as	fasting	plasma	glucose	≥7.0	mmol/l	or	on	anti-diabetic	treatment	22	e	Cardio-	and	cerebrovascular	disease	of	first-degree	relatives	(men<55years,	women<65years)	21	f	21	missing	values	for	self-reported	alcohol	consumption.	
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Table	2:		
Multivariate	longitudinal	analysis	of	the	effect	of	cardiovascular	risk	factors	on	carotid	intima-media	thickness	at	
baseline	and	on	its	progression	over	3	years	of	follow-up.	
		 Baseline	(n=260)	 1-year	follow-up	(n=219)	 3-year	follow-up	(n=177)		 Estimateb	 P	value	 95%	CI	 Estimateb	 P	value	 95%	CI	 Estimateb	 P	value	 95%	CI	Mean	CIMT-max	at	baseline	and	progression,	μm	 1184.6	 	 1082.1	 1287.0	 93.0	 	 25.3	 160.6	 108.2	 	 33.2	 183.2	Male	sex	 157.6	 0.04	 7.1	 308.2	 2.3	 0.96	 -90.6	 95.1	 2.2	 0.97	 -99.5	 103.8	Age	(per	10	years)	 429.3	 <0.001	 291.6	 567	 36.3	 0.40	 -47.6	 120.2	 -9.4	 0.83	 -98.1	 79.2	Log	number	of	cigarettes	per	day	at	baseline	 196.1	 0.03	 20.6	 371.6	 -9.8	 0.86	 -119.6	 100.1	 -96.5	 0.11	 -214.9	 21.9	Years	of	smoking	 4.2	 0.49	 -7.7	 16.1	 -3.5	 0.35	 -10.8	 3.8	 -5.0	 0.20	 -12.6	 2.6	SBP	at	baseline	(per	10	mmHg)	 50.8	 0.03	 5.9	 95.8	 26.1	 0.06	 -1.5	 53.7	 39.0	 0.01	 9.2	 68.7	LDL	cholesterol	at	baseline,	mmol/l	 51.4	 0.14	 -16.9	 119.7	 27.5	 0.21	 -15.2	 70.3	 6.9	 0.78	 -40.4	 54.1	HDL	cholesterol	at	baseline,	mmol/l	 -123.0	 0.19	 -308.5	 62.6	 -43.4	 0.48	 -164.7	 77.9	 74.5	 0.27	 -59.0	 208.1	Fasting	plasma	glucose	at	baseline,	mmol/l	 -26.2	 0.52	 -105.6	 53.2	 11.4	 0.68	 -42.8	 65.7	 -68.5	 0.03	 -128.6	 -8.4	Log	hs-CRP	at	baseline,	mg/dl	 -35.5	 0.30	 -103.2	 32.1	 -14.1	 0.51	 -56.1	 28.0	 25.2	 0.29	 -21.2	 71.5	Smoking	abstinencea	 	 	 	 	 	 	 	 	 	 	 	 	1-year	relapse	(reference	category)	 n/a	 	 	 	 ref.	 	 	 	 ref.	 	 	 	1-year	abstinent	/	3-year	relapse	 n/a	 	 	 	 -24.1	 0.61	 -115.7	 67.6	 -67.3	 0.47	 -251.7	 117.2	3-year	abstinent	 n/a	 	 	 	 -24.1	 0.61	 -115.7	 67.6	 -16.0	 0.76	 -119.2	 87.2		Abbreviations:	CIMT-max,	carotid	intima-media	thickness;	HDL,	high-density	lipoprotein;	hs-CRP,	high-sensitivity	C-reactive	protein;	LDL,	low-density	lipoprotein;	SBP,	systolic	blood	pressure.	a	Numbers	of	participants	in	categories	of	smoking	abstinence:	1-year	relapse:	n=208;	1-year	abstinent/3-year	relapse:	n=13;	3-year	continuously	abstinent:	n=39	b	Estimates	in	the	first	line	of	the	table	indicate	the	actual	mean	thickness	of	CIMT	(in	micrometers),	determined	by	all	cardiovascular	risk	factors	mentioned	in	the	table	(baseline	CIMT=1185μm).	Estimates	in	the	other	lines	of	the	table	(except	line	1)	correspond	to	change	in	CIMT	(in	micrometer)	associated	with	a	one-unit	change	of	a	risk	factor	at	baseline,	adjusted	to	all	covariates	mentioned	in	the	table.	Estimates	at	1	year	refer	to	change	in	CIMT	between	baseline	and	1	year,	and	estimates	at	3	years	refer	to	change	in	CIMT	between	baseline	and	3	years.	
